Alpine Immune Sciences Inc banner
A

Alpine Immune Sciences Inc
F:34LA

Watchlist Manager
Alpine Immune Sciences Inc
F:34LA
Watchlist
Price: 59 EUR Market Closed
Market Cap: €4B

Alpine Immune Sciences Inc
Other Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Alpine Immune Sciences Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
A
Alpine Immune Sciences Inc
F:34LA
Other Equity
-$263k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Equity
-$1.1B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Other Equity
$31m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Other Equity
$8.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Equity
-$49.9m
CAGR 3-Years
N/A
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Equity
$77.5m
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
25%
No Stocks Found

Alpine Immune Sciences Inc
Glance View

Market Cap
4B EUR
Industry
Biotechnology

Alpine Immune Sciences Inc., a biotechnology company, stands poised at the intersection of innovation and necessity, carving its niche in the fast-paced world of immune system modulation. Founded to address the complex challenges of autoimmune inflammation and cancer, Alpine harnesses the intricate mechanisms of the immune system to develop novel therapies. The company's unique approach centers around their proprietary platform, the "Directed Evolution" technique, which enhances the body's natural defenses by evolving proteins to selectively target cells and pathways. This approach aims to balance efficacy with safety—a critical factor in immunotherapy—to not just treat but possibly transform the landscape of autoimmune and cancer treatments. In this innovative pursuit, Alpine generates revenue through a multi-pronged business model, leveraging both partnerships and proprietary product development. The company actively collaborates with big-name players in the pharmaceutical industry, securing milestone payments, and royalties that provide financial footing. Their pipeline, rich with potential candidates, further positions Alpine for future commercial success, especially as its therapies advance into later stages of clinical trials. By focusing on high-need areas and utilizing strategic collaborations, Alpine Immune Sciences is steadily building a sustainable business model while offering a beacon of hope for patients looking for more effective treatment options.

34LA Intrinsic Value
Not Available
A

See Also

What is Alpine Immune Sciences Inc's Other Equity?
Other Equity
-263k USD

Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's Other Equity amounts to -263k USD.

What is Alpine Immune Sciences Inc's Other Equity growth rate?
Other Equity CAGR 1Y
34%

Over the last year, the Other Equity growth was 34%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett